BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 19, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

May 4, 2018

View Archived Issues

FDA grants orphan drug designation to BN-Brachyury as treatment for chordoma

Read More

Refuge Biotechnologies completes series B financing

Read More

Azitra raises new financing to advance pipeline

Read More

Coherus BioSciences announces re-submission of BLA for CHS-1701

Read More

Daiichi Sankyo profiles highlights of fourth quarter of fiscal 2017

Read More

Abbisko presents novel candidates with promising preclinical profiles

Read More

Phase I results reported for analgesic CCR2 antagonist CNTX-6970

Read More

RBH-61, a dual SEH/PDE inhibitor for inflammatory pain

Read More

FDA grants two fast track designations for 5F9

Read More

Ocular Therapeutix doses first patient in phase I clinical trial of OTX-TIC

Read More

Bristol-Myers Squibb presents new apelin receptor agonists

Read More

Ferring Pharmaceuticals acquires option to commercialize nadofaragene firadenovec/Syn3

Read More

AbbVie divulges novel BRD4 inhibitors

Read More

Jiangsu Hengrui Medicine and collaborator disclose TGFR-1 inhibitors

Read More

Sanofi reviews key events of first quarter 2018

Read More

Phase III trial of ranibizumab biosimilar FYB-201 meets primary endpoint

Read More

RTI International discovers new APLNR agonists

Read More

Dong-A Socio Holdings identifies Mer inhibitors

Read More

Phase I trial begins of CS-1002 for advanced solid tumors begins in Australia

Read More

FDA joint advisory committee meeting recommends against stannsoporfin

Read More

Moderna Therapeutics and Merck & Co. expand cancer collaboration

Read More

New albumin-binding compounds from CytRx show antitumor activity in xenograft models

Read More

FDA approves AndexXa to reverse factor Xa inhibitors

Read More

Altum Pharmaceuticals acquires Lexi Pharma

Read More

First patient dosed in phase II study of AG-10 in ATTR cardiomyopathy

Read More

DLK inhibitor shows promising data in vivo

Read More

Casma Therapeutics launched to develop breakthrough therapies by boosting autophagy

Read More

OTL-200 receives rare pediatric disease designation from the FDA

Read More

EMA validates type II variation application for Opdivo plus Yervoy in first-line NSCLC

Read More

Sarepta partners with Myonexus to advance gene therapies for limb-girdle muscular dystrophy

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 19, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 19, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Rare disease illustration

    Rare earth: Biomarin to use global reach post-$4.8B Amicus buy

    BioWorld
    Biomarin Pharmaceutical Inc. followed up its May takeover of Inozyme Pharma Inc. with a much larger agreement to acquire Amicus Therapeutics Inc. for $14.50 per...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing